WallStSmart

Uber Technologies Inc (UBER)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Uber Technologies Inc generates 339% more annual revenue ($53.69B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 15.9%. VRTX appears more attractively valued with a PEG of 2.10. VRTX earns a higher WallStSmart Score of 66/100 (B-).

UBER

Buy

54

out of 100

Grade: C-

Growth: 5.3Profit: 7.5Value: 6.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.47

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

UBERUndervalued (+34.1%)

Margin of Safety

+34.1%

Fair Value

$108.26

Current Price

$75.45

$32.81 discount

UndervaluedFair: $108.26Overvalued
VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

UBER3 strengths · Avg: 9.0/10
Return on EquityProfitability
35.3%10/10

Every $100 of equity generates 35 in profit

Market CapQuality
$156.19B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.29B8/10

Generating 2.3B in free cash flow

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

UBER3 concerns · Avg: 2.0/10
PEG RatioValuation
4.512/10

Expensive relative to growth rate

EPS GrowthGrowth
-84.6%2/10

Earnings declined 84.6%

Altman Z-ScoreHealth
1.472/10

Distress zone — elevated risk

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : UBER

The strongest argument for UBER centers on Return on Equity, Market Cap, Free Cash Flow. Profitability is solid with margins at 15.9% and operating margin at 14.6%. Revenue growth of 14.5% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : UBER

The primary concerns for UBER are PEG Ratio, EPS Growth, Altman Z-Score.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

UBER carries more volatility with a beta of 1.16 — expect wider price swings.

UBER is growing revenue faster at 14.5% — sustainability is the question.

UBER generates stronger free cash flow (2.3B), providing more financial flexibility.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (66/100 vs 54/100), backed by strong 35.5% margins. UBER offers better value entry with a 34.1% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Uber Technologies Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Uber Technologies, Inc., commonly known as Uber, is an American technology company. Its services include ride-hailing, food delivery (Uber Eats), package delivery, couriers, freight transportation, and, through a partnership with Lime, electric bicycle and motorized scooter rental. The company is based in San Francisco, California.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?